QUANTUM BIOPHARMA-B SUB VOT
QNTMNASDAQTrading Snapshot
- Day Range
- $3.45 – $3.48
- 52-Week Range
- $2.85 – $43.00
- Volume
- $2.90B
- Avg Volume
- $2.80B
- Shares Outstanding
- 6.4M
- Next Earnings
- Sep 20, 2026
Fundamentals Snapshot
- Annual Revenue
- $5M
- Last Q Revenue
- $1M
- P/E Ratio
- —
- P/S Ratio
- 133.0x
- EPS (TTM)
- $-8.27
- Dividend Yield
- —
Why Investors Own QNTM
- ✓High-growth profile — revenue up +10.1% YoY with expanding US Equity exposure.
- ✓Healthy economics — 47% gross margin and 22% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
About QUANTUM BIOPHARMA-B SUB VOT
Quantum BioPharma Ltd., a biopharmaceutical firm headquartered in Toronto, Canada, is dedicated to the discovery and advancement of biotechnological solutions and drug candidates. The company focuses on addressing complex neurodegenerative, inflammatory, and metabolic conditions, alongside alcohol use disorder, with its pipeline featuring a range of drug candidates at varying stages of development. Its operations are divided into two main divisions: its core biopharmaceutical activities and strategic investment holdings. A flagship asset is Lucid-MS, a novel, proprietary chemical entity currently in Phase 2 clinical trials. Preclinical data indicates its potential to prevent and reverse the degradation of myelin, a key process underlying multiple sclerosis. Furthermore, Quantum BioPharma is developing a therapeutic solution for alcohol addiction, intended for application in hospital and clinical environments. The company's strategic investments portfolio includes various loans collateralized by residential real estate. Previously known as FSD Pharma Inc., the company adopted its current name, Quantum BioPharma Ltd., in August 2024.
Otter Score Breakdown
ⓘAnalyst Ratings
ⓘLatest News & Updates
EXCLUSIVE: Quantum BioPharma Achieves Major Milestone With FDA Clearance for Multiple Sclerosis Trial
FDA approves Quantum BioPharma's IND application for Lucid-MS, advancing its progressive multiple sclerosis treatment to Phase 2 trials.
Quantum BioPharma Announces Closing of Debt Settlement
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 30, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metab
Quantum BioPharma (QNTM) Executive Outlines Lucid-MS Development Strategy and Commercial Growth Plans
LOS ANGELES, CA - July 28, 2026 (NEWMEDIAWIRE) - Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies and technologies, was featured in a recent episode of the BioMedWire Podcast. During ...
Quantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting Millions
Quantum BioPharma's MS focus is Lucid-MS, a patented new chemical entity that takes a fundamentally different approach from existing therapies. Supporting Lucid-MS's phase 2 development is an ongoing imaging collaboration with Massachusetts General ...
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Gainers Jupiter Neurosciences (NASDAQ:JUNS) stock rose 36.4% to $0.23 during Tuesday's pre-market session. The market value of their outstanding shares is at $7.9 million. Imunon (NASDAQ:IMNN) shares moved upwards
Quantum BioPharma Announces Intention to Settle Debt
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, July 20, 2026 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metab